Loading clinical trials...

A Study Of PF-03732010 In Patients With Advanced Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03732010 In Patients With Advanced Solid Tumors

NCT00557505•Pfizer

Summary

P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Advanced solid tumors refractory to (or intolerant of) established therapy known to provide clinical benefit, or for which there is no standard therapy
•Age \>= 18 years of age
•Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1500/uL, hemoglobin ≥ 9 g/dL, platelets \> 100,000/uL
•Adequate liver function as defined by: bilirubin \< 1.5 x ULN, AST, ALT and ALP \< 2.5 x ULN, or \< 5 x ULN with documented liver and/or bone metastases
•Serum creatinine \< 1.5 x ULN
•ECOG status 0-1
•Availability of biopsy tumor tissue (or fine needle aspirate) for testing of P-cadherin expression
•Tumor tissue (or fine needle aspirate) showing over-expression of P-cadherin
•Must be able to give written informed consent
•Be able to comply with scheduled study visits, treatment plans, laboratory tests and other procedures

Exclusion Criteria

•Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of study entry
•Patients with carcinomatous meningitis or untreated brain metastases.
•History of significant low platelet count, and/or bleeding disorders, requiring medical or surgical intervention
•History of significant bleeding episodes within 6 months, unless the source of bleeding has been resected

Locations (3)

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Pfizer Investigational Site

Parkville, Victoria, Australia

Pfizer Investigational Site

Seoul, South Korea

Key Dates

Start Date

December 1, 2007

Primary Completion Date

February 1, 2011

Completion Date

February 1, 2011

Last Updated

March 26, 2012

Enrollment

ACTUAL participants

Conditions

Neoplasms

Interventions

PF-03732010

DRUG

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGPHASE3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 26, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients